Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 - DelveInsight

DelveInsight's "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Multiple Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Sclerosis Market Forecast
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Multiple Sclerosis Market Report:
• The Multiple Sclerosis market size in the 7MM was valued at USD 21,831 million in 2025 and is projected to grow at a CAGR of 3.8%, reaching USD 30,597 million by 2034 across key markets, including the US, EU4, UK, and Japan.
• In August 2026, Quantum BioPharma Ltd. (NASDAQ: QNTM; CSE: QNTM; FRA: 0K91), a biopharmaceutical company focused on developing innovative therapies and biotechnology solutions for neurological, metabolic, and alcohol misuse disorders, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302). The regulatory milestone allows the company to move its patented, first-in-class multiple sclerosis program into Phase II clinical development. The program will evaluate the novel Lucid-MS chemical entity in patients with MS, with the goal of potentially improving or reversing aspects of impaired mobility and loss of bodily control associated with the disease.
• In May 2026, Regulatory momentum in the neurology space remained strong, with multiple FDA reviews and development milestones reported across neurological disorders, including continued advancements in the multiple sclerosis pipeline. Meanwhile, companies continued to advance late-stage MS candidates and prepare for upcoming regulatory filings.
• In January 2026, The FDA has approved ScinoPharm Taiwan's glatiramer acetate (GA) injection for the treatment of relapsing multiple sclerosis (MS), marking the first approval of a complex generic injectable for this therapy, according to a recent announcement.
• In December 2025, The U.S. FDA has granted tentative approval to Lupin's Siponimod tablets, a bioequivalent version of Mayzent (siponimod), for treating relapsing forms of multiple sclerosis (MS). According to a company press release, the therapy is approved for adults with clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS). Like Novartis' Mayzent tablets, Lupin's generic will be offered in three strengths: 0.25 mg, 1 mg, and 2 mg.
• In 2024, the US Multiple Sclerosis market was valued at around USD 16,000 million and is expected to grow with the introduction of emerging therapies.
• In September 2025, Zydus Lifesciences announced on Thursday that its subsidiary has partnered with Netherlands-based Synthon BV to launch a generic drug for treating multiple sclerosis in the US. Zydus Lifesciences Global FZE has secured an exclusive licensing and supply agreement with Synthon BV for Ozanimod capsules, a generic version of ZEPOSIA, for the US market, according to a regulatory filing.
• In Sepetmber 2025, A generic version of Zeposia (ozanimod), which has received tentative approval from the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS), will be produced and supplied by the Netherlands-based Synthon. Tentative approval indicates that the generic version has met all FDA standards for safety, efficacy, and quality. However, it cannot be marketed yet due to existing patent protections or exclusivity rights held by the brand-name drug.
• In September 2025, Sanofi's journey to secure regulatory approval for its investigational multiple sclerosis drug has hit another setback, as the FDA has decided to delay its approval decision by three months. Tolebrutinib, a BTK inhibitor acquired by Sanofi through its $3.7 billion purchase of Principia Biopharma in 2021, had been on track for an FDA decision by September 28, following a priority review earlier this year. Sanofi is seeking approval for the drug to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow the accumulation of disability in adult patients, independent of relapse activity.
• In June 2025, Ashvattha Therapeutics announced at the SNMMI Annual Meeting that its nanomedicines can be tailored to visualize neuroinflammation in patients with Multiple Sclerosis.
• In June 2025, IASO Bio showcased encouraging results of Equecabtagene Autoleucel in Multiple Sclerosis patients from an IIT study during the 11th Congress of the EAN.
• In June 2025, Telomir Pharmaceuticals announced that Telomir-1 resets the body's epigenetic clock, reverses DNA methylation, and restores gene regulation in patients with Werner Syndrome.
• In May 2025, TG Therapeutics announced upcoming data presentations on BRIUMVI for Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
• In May 2025, Immunic announced its intention to continue developing vidofludimus calcium (IMU-838), its investigational therapy for multiple sclerosis (MS), despite the Phase II trial not achieving its primary endpoint. Initial findings from the ongoing CALLIPER study (NCT05054140) indicated a slight benefit in an exploratory MRI-based primary measure, with a 5% annualized reduction in brain volume loss compared to placebo.
• In March 2025, The U.S. FDA has granted Priority Review to Sanofi's regulatory application for tolebrutinib, based on favorable results from the Phase III HERCULES (NCT04411641), GEMINI 1 (NCT04410978), and GEMINI 2 (NCT04410991) trials. This submission aims to secure approval for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS) and focuses on slowing disability progression not linked to relapse activity in adults.
• In February 2025, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) announced the successful completion of its Phase 1 trial titled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." The final review by the Safety Review Committee (SRC) confirmed that Lucid-21-302 (Lucid-MS) was well-tolerated, with no safety issues or serious adverse events observed. Lucid-MS is a first-in-class, neuroprotective agent without immunomodulatory effects, currently in development for treating multiple sclerosis (MS).
• In January 2025, Pheno Therapeutics secured clinical trial authorization (CTA) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to begin testing its small-molecule therapy, PTD802. This approval allows the launch of the first-in-human trial for PTD802, a selective antagonist of G protein-coupled receptor 17 (GPR17), aimed at enhancing remyelination in individuals with neurological conditions, especially multiple sclerosis (MS).
• In January 2025, Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on novel treatments for neuroscience, inflammation, and immunology (NI&I) disorders, announced the successful completion of enrollment for its Phase 2 PIPE-307 VISTA trial. The study has enrolled 168 participants and is investigating PIPE-307, a potentially first-in-class M1 receptor antagonist, as a treatment option for relapsing-remitting multiple sclerosis (RRMS).
• In 2023, there were 728,000 prevalent cases of multiple sclerosis in the US, and this number is projected to undergo significant changes by 2034.
• In 2023, when the prevalent cases of multiple sclerosis in Germany were analyzed by gender, there were approximately 61,000 cases among males and 150,000 cases among females.
• In the UK, when multiple sclerosis cases were categorized by phenotype, a significant difference was observed, with RRMS being more prevalent than Clinically Isolated Syndrome, SPMS, and PPMS. In 2023, around 80,000 major cases of multiple sclerosis were recorded under the RRMS subtype, and these numbers are anticipated to fluctuate further during the study period from 2020 to 2034.
• In 2023, Japan recorded about 5,000 prevalent cases of multiple sclerosis, with expectations that these numbers will fluctuate further by 2034.
• Key Multiple Sclerosis Companies: Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others
• Key Multiple Sclerosis Therapies: BIIB091, NeuroVax, IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others
• The Multiple Sclerosis epidemiology based on gender analyzed that in the United States, the prevalence of Multiple Sclerosis is higher in females as compared to males
• The Multiple Sclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Sclerosis pipeline products will significantly revolutionize the Multiple Sclerosis market dynamics.
• The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat Multiple Sclerosis. However, large multicenter trials are still necessary to examine the overarching patterns of Multiple Sclerosis and treatment response as a whole.

Multiple Sclerosis Overview
Multiple sclerosis (MS) is a chronic autoimmune disease where the immune system attacks the protective covering (myelin) of nerve fibers in the central nervous system (CNS). This damage disrupts communication between the brain and the rest of the body, leading to symptoms such as fatigue, muscle weakness, vision problems, and coordination issues. The exact cause of MS is unknown, but it is thought to involve a combination of genetic and environmental factors.

Get a Free sample for the Multiple Sclerosis Market Report:
https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Multiple Sclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple Sclerosis Epidemiology Segmentation:
The Multiple Sclerosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Multiple Sclerosis
• Prevalent Cases of Multiple Sclerosis by severity
• Gender-specific Prevalence of Multiple Sclerosis
• Diagnosed Cases of Episodic and Chronic Multiple Sclerosis

Download the report to understand which factors are driving Multiple Sclerosis epidemiology trends @ Multiple Sclerosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched during the study period. The analysis covers Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple Sclerosis Therapies and Key Companies
• BIIB091: Biogen
• NeuroVax: Immune Response BioPharma
• IMCY-0141: ImCyse
• ATA188: Atara Biotherapeutics
• EHP-101: Emerald Health Pharmaceuticals
• SAR441344: Sanofi
• RC18: RemeGen
• GB7208: Gossamer Bio
• MRx0002: 4D Pharma
• HuL001: HuniLife Biotechnology
• ANK-700: Anokion
• GSK3888130: GSK plc
• Temelimab: GeNeuro
• IMU-838: Immunic Therapeutics
• Tolebrutinib: Sanofi
• Fenebrutinib: Hoffman-La-Roche

Discover more about therapies set to grab major Multiple Sclerosis market share @ Multiple Sclerosis Treatment Market
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Multiple Sclerosis Market Drivers
• Increasing prevalence and improved diagnosis of Multiple Sclerosis (MS) are expanding the patient pool and driving demand for effective therapies.
• Continuous advancements in disease-modifying therapies (DMTs), including monoclonal antibodies and next-generation oral treatments, are improving disease management and market growth.
• Growing focus on progressive forms of MS, particularly primary progressive and secondary progressive MS, is encouraging the development of novel therapeutic options.
• Rising investments in research and clinical trials by pharmaceutical companies and academic institutions are accelerating pipeline innovation.

Multiple Sclerosis Market Barriers
• High cost of disease-modifying therapies and biologics can limit patient access and place a significant burden on healthcare systems.
• Lack of curative treatments, with current therapies primarily focused on slowing disease progression and reducing relapse frequency rather than reversing neurological damage.
• Complex disease heterogeneity and unpredictable progression make treatment optimization and clinical trial design challenging.
• Safety concerns and long-term adverse effects associated with immunosuppressive and immunomodulatory therapies may affect patient adherence.

Scope of the Multiple Sclerosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Multiple Sclerosis Companies: Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others
• Key Multiple Sclerosis Therapies: BIIB091, NeuroVax, IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others
• Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies
• Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Multiple Sclerosis Unmet Needs, KOL's views, Analyst's views, Multiple Sclerosis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.